Kura Oncology Reports Third Quarter 2022 Financial Results
November 03, 2022 07:30 ET
|
Kura Oncology, Inc.
– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC – – AIM-HN...
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
October 26, 2022 07:30 ET
|
Kura Oncology, Inc.
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors...
Kura Oncology to Participate in H.C. Wainwright Global Investment Conference
September 01, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Second Quarter 2022 Financial Results
August 03, 2022 16:03 ET
|
Kura Oncology, Inc.
– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – ...
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Second Quarter 2022 Financial Results
July 27, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Three Upcoming Investor Conferences
May 26, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2022 Financial Results
May 04, 2022 16:05 ET
|
Kura Oncology, Inc.
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in...
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
April 08, 2022 13:00 ET
|
Kura Oncology, Inc.
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – –...
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
March 08, 2022 17:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...